Mostrar el registro sencillo del ítem
dc.contributor.author | Vicent, Lourdes | |
dc.contributor.author | Juárez Fernández, Miriam | |
dc.contributor.author | Martín, Isbelia | |
dc.contributor.author | García, J. | |
dc.contributor.author | González Saldivar, Hugo | |
dc.contributor.author | Bruña Fernández, Vanesa | |
dc.contributor.author | Devesa Cordero, Carolina | |
dc.contributor.author | Sousa Casasnovas, Iago | |
dc.contributor.author | Fernández-Avilés, Francisco | |
dc.contributor.author | Martínez Sellés Oliveria Soares, Manuel | |
dc.date.accessioned | 2018-05-14T06:50:09Z | |
dc.date.available | 2018-05-14T06:50:09Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Vicent, L., Juárez, M., Martín, I., García, J., González-Saldívar, H., Bruña, V., ... & Martínez-Sellés, M. (2018). Ventricular Arrhythmic Storm after Initiating Sacubitril/Valsartan. Cardiology, 139(2), 119-123. DOI: 10.1159/000486410 | spa |
dc.identifier.issn | 0008-6312 | |
dc.identifier.issn | 1421-9751 | |
dc.identifier.uri | http://hdl.handle.net/11268/7260 | |
dc.description.abstract | Objectives: Sacubitril/valsartan was approved recently for the treatment of patients with heart failure and reduced ejection fraction. We present 6 cases of ventricular arrhythmia, that occurred shortly after sacubitril/valsartan initiation, that required drug withdrawal. Other potential triggering factors of electrical storm were ruled out and, from the arrhythmic perspective, all of the patients were stable in the previous year. Our aim is to describe the possible association of sacubitril/valsartan with arrhythmic storm. Methods: This was an observational monocentric study performed in the first 7 months of sacubitril/valsartan commercialization in Spain (October 2016). All patients were included in the SUMA (Sacubitril/Varsartan Usado Ambulatoriamente en Madrid [Sacubitril/Valsartan Used in Outpatients in Madrid]) registry. Patients were consecutively enrolled on the day they started the drug. Ventricular arrhythmic storm was defined as ≥2 episodes of sustained ventricular arrhythmia or defibrillator therapy application in 24 h. Results: From 108 patients who received the drug, 6 presented with ventricular arrhythmic storm (5.6%). Baseline characteristics were similar in the patients with and without ventricular arrhythmic storm. The total number of days that sacubitril/valsartan was administered to each patient was 5, 6, 44 (8 since titration), 84, 93, and 136 (105 since titration), respectively. Conclusions: Our data are not enough to infer a cause-and-effect relationship. Further investigations regarding a potential proarrhythmic effect of sacubitril/valsartan are probably needed. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.title | Ventricular Arrhythmic Storm after Initiating Sacubitril/Valsartan | spa |
dc.type | article | spa |
dc.description.impact | 1.561 JCR (2018) Q4, 103/136 Cardiac & Cardiovascular Systems | spa |
dc.description.impact | 0.837 SJR (2018) Q2, 109/365 Cardiology and Cardiovascular Medicine, 92/268 Pharmacology (medical) | spa |
dc.description.impact | No data IDR 2018 | spa |
dc.identifier.doi | 10.1159/000486410 | |
dc.rights.accessRights | closedAccess | spa |
dc.subject.uem | Arritmia | spa |
dc.subject.uem | Insuficiencia cardíaca | spa |
dc.subject.unesco | Enfermedad cardiovascular | spa |
dc.subject.unesco | Tratamiento médico | spa |
dc.description.filiation | UEM | spa |
dc.peerreviewed | Si | spa |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |